This study investigates advanced gastric cancer and pancreatic cancer. It focuses on evaluating the investigational treatment Claudin18.2CAR-T, which targets specific proteins found in these cancers.
The purpose of this study is to evaluate the safety and effectiveness of Claudin18.2CAR-T cells. Researchers are interested in how well this treatment works in improving outcomes for patients with these advanced cancers.
- Who can participate: Adults aged 18 to 75 with advanced gastric or pancreatic cancer may join. Participants must have received prior standard treatments and have measurable disease. Claudin 18.2 expression in tumor tissues is required.
- Study details: Participants will receive the investigational treatment. Some may receive a placebo, an inactive substance that looks like the investigational medicine but does not contain any medicine.
How understandable was the trial content above?
Hard to understand
Easy to understand